# Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Gerald S. Falchook,Karl D. Lewis,Jeffrey R. Infante,Michael S. Gordon,Nicholas J. Vogelzang,Douglas J. DeMarini,Peng Sun,Christopher Moy,Stephen A. Szabo,Lori Roadcap,Vijay Peddareddigari,Peter F. Lebowitz,Ngocdiep T. Le,Howard A. Burris,Wells A. Messersmith,Peter J. O’Dwyer,Kevin B. Kim,Keith T. Flaherty,Johanna C. Bendell,René González,Razelle Kurzrock,Leslie A. Fecher |
| Citations | 545 |
| DOI | 10.1016/s1470-2045(12)70269-3 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/4109286 |
| OpenAlex ID | https://openalex.org/W1988379285 |
| PMID | 22805292 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Leslie A. Fecher](https://scholariq.org/researchers/leslie-a-fecher/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Paper topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Ocular Oncology and Treatments](https://scholariq.org/topics/ocular-oncology-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.